Filter By Category
Archives
Share on -
AVAPRITINIB
Generic Name: AVAPRITINIB
ABSTRACT -
Avapritinib is an oral small-molecule tyrosine kinase inhibitor targeting KIT and PDGFRA mutations where approved for selected gastrointestinal stromal tumor and systemic mastocytosis settings. Its molecular formula is C₂₆H₂₇FN₁₀. The chemical representation above shows the 2D skeletal structure.
This document is for structured API information only. It is not a prescribing guide. Clinical use, if any, must follow the approved local label, trial protocol, and specialist medical supervision.
DOSAGE -
- Dosage should be determined only by a qualified healthcare professional.
- Use only according to the approved local product label for the specific indication.
- Dose, duration, and monitoring requirements may differ by disease, organ function, age, and interacting medicines.
- Do not change, stop, or restart treatment without medical supervision.
SIDE EFFECTS-
Possible side effects and safety concerns include:
- Edema, nausea, vomiting, diarrhea, abdominal pain, or fatigue
- Anemia, thrombocytopenia, neutropenia, or bleeding risk
- Cognitive effects, dizziness, mood changes, or sleep disturbance
- Rash, hair-color changes, or increased lacrimation
- Intracranial bleeding has been reported and requires urgent evaluation
ALLERGIC REACTIONS -
Hypersensitivity to Avapritinib or related compounds/products may occur. Symptoms may include:
- Immediate urticaria, itching, flushing, or generalized rash
- Facial, lip, tongue, or throat swelling
- Wheezing, chest tightness, or breathing difficulty
- Dizziness, fainting, severe hypotension, or collapse
- Anaphylaxis, although uncommon, requires emergency medical treatment
Important: Patients who develop an allergic reaction to Avapritinib should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS-
Avapritinib may interact with certain medicines, biologics, vaccines, protocols, or clinical conditions. Caution is needed with:
- Strong CYP3A inhibitors or inducers may alter avapritinib exposure.
- Anticoagulants or antiplatelet medicines may increase bleeding risk.
- Other CNS-active medicines may worsen cognitive or sedating effects.
- Patients should report all medicines, herbal products, and supplements.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, vaccines, and supplements they are using.
PREAUTIONS–
- Monitor blood counts, bleeding symptoms, and cognitive changes.
- Use caution in patients with bleeding risk or prior intracranial events.
- Avoid pregnancy exposure; use effective contraception as directed.
- Dose interruption or modification may be required for significant toxicity.
WARNINGS –
- Intracranial bleeding, severe cognitive effects, or severe cytopenias require immediate medical review.
- Use only for molecularly appropriate disease under oncology/hematology supervision.
- Do not use during pregnancy unless the benefit clearly outweighs risk.
- Keep out of reach of children.
Share on -
. Developed by